Eisai has adopted Medidata's Clinical Data Studio, which aims to transform and modernising the clinical trial efficiency and patient experience.
Launched last month, this AI-driven platform is expected to grant Eisai control over its clinical data, facilitate the execution of scalable and complex trials, and enhance the overall patient experience.
The Clinical Data Studio is a component of the Medidata platform, which centrally manages data from various sources. This integration could be crucial for improving data reliability across the entire trial ecosystem, the company noted.
Medidata global head of sales and executive vice-president Janet Butler said: “Through Clinical Data Studio, Eisai is enabling healthcare stakeholders to overcome the complexities of modern clinical trials and foster collaboration on cleaner, more actionable data.”
By combining data from Medidata sources such as Medidata Rave EDC and external sources, including laboratories or alternative electronic data capture systems, the Clinical Data Studio simplifies the data import process.
This approach also aids in automatic validation by configuring data transfer agreements.
The platform's AI capabilities address the challenges of disparate data systems, offering up to an 80% quicker data review process. It also provides a comprehensive patient data view that can be reviewed, visualised, and acted upon simultaneously.
Eisai chief clinical science and operations officer Shobha Dhadda said: “We’ve included Medidata’s Clinical Data Studio in our clinical trial management platform given its ability to break down data silos and seamlessly integrate into our current software stack, while maintaining quality and integrity across all data sources.
“Having a suite of technology solutions capable of processing diverse clinical and patient data types provides increased efficiencies without sacrificing quality or needing additional resources.”
In May, Lexicon Pharmaceuticals selected Medidata to support its Phase IIb PROGRESS study of LX9211, a non-opioid candidate for the treatment of diabetic peripheral neuropathic pain.
